Egle Therapeutics
egle-tx.com
Actively hiring
Biotechnology
Immunology & Inflammation Therapeutics
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Egle Therapeutics to Present Clinical Data at the Upcoming European Academy of Dermatology and Venereology (EADV) Congress in Vienna
Egle to share clinical data on EGL-003, the company's most advanced Treg-selective IL-2 agonist for atopic dermatitis Paris, France, (September 15, 2026) - Egle Therapeutics ("Egle"), a clinical-stage biotechnology company advancing a proprietary therapeu
Read more
Report
Egle Therapeutics to Present Clinical Data at the Upcoming European Academy of Dermatology and Venereology (EADV) Congress in Vienna
Egle to share clinical data on EGL-003, the company
Read more
Report
Egle Therapeutics and Consortium Partners Awarded €8 Million Grant from Horizon Europe to Advance Clinical Development of EGL-001 in Neoadjuvant Head and Neck Cancer
PARIS, March 02, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in patients with autoimmune diseases and ca
Read more
Report
Egle Therapeutics and Consortium Partners Awarded €8 Million Grant from Horizon Europe to Advance Clinical Development of EGL-001 in Neoadjuvant Head and Neck Cancer
Paris, France, March 2, 2026 - Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in patients with autoimmune diseases and cancer, today
Read more
Report
Egle Therapeutics Appoints John Celebi as Chief Executive Officer
Paris, France, Jan. 7, 2026 - Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in patients with autoimmune diseases and cancer, today
Read more
Report
Pro access
Upgrade to see all 17 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
People
John Celebi
Président de SAS
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Suresnes
France
HQ
EGLE THERAPEUTICS SAS
5 Rue Gardenat Lapostol, 92150 Suresnes, France